Edesa Biotech
EDSA

$4.35

3.08%

Market Cap: $14.1M

About: Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Employees: 16

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

43% more capital invested

Capital invested by funds: $451K [Q1] → $645K (+$194K) [Q2]

1.28% more ownership

Funds ownership: 3.4% [Q1] → 4.68% (+1.28%) [Q2]

0% more funds holding

Funds holding: 17 [Q1] → 17 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$21

383%

upside

Avg. target

$21

383%

upside

High target

$21

383%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Vernon Bernardino 37% 1-year accuracy 18 / 49 met price target	383%upside $21	Buy Reiterated	20 Aug 2024
HC Wainwright & Co. Vernon Bernardino 37% 1-year accuracy 18 / 49 met price target	383%upside $21	Buy Reiterated	28 Jun 2024

See Analyst Rankings

Financial journalist opinion

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants of restricted share units (“RSUs”) of Edesa Biotech, Inc. (“Edesa”), when combined with a series of transactions (the “Transactions”) that have occurred since the date of the most recent early warning report filed by Dr. Nijhawan on November 18, 2022 (the “Previous Report”), Dr. Nijhawan has acquired “beneficial ownership” of common shares in the capital of Edesa (“Common Shares”) in an amount equal to more than 2% of the issued and outstanding Common Shares since the date of the Previous Report.

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2024 and provided an update on its business.

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS.

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an update on its business. During the quarter, the company expanded site selection activities for a Phase 3 study of its ARDS (Acute Respiratory Distress Syndrome) drug candidate, EB05 (paridiprubart).

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 16-17, 2024 in Toronto, Ontario. Edesa's Chief Executive Officer Par Nijhawan, MD, is scheduled to present on Wednesday, April 17 at 11:00 am ET.

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech to Participate in Upcoming Investor Conferences

TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management plans to participate in the following upcoming investor conferences: Mintz Conference, Toronto, Canada, April 15, 2024 LSX World Congress, London, UK, April 29-30, 2024, with showcase presentation at 4:30 pm GMT on April 29, 2024 RBC Capital Markets Global Healthcare Conference, New York, NY, May 14-15, 2024 To schedule a meeting with Edesa during the conference, please contact conference organizers or the company directly at investors@edesabiotech.com. About Edesa Biotech Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases.

Edesa Biotech to Participate in Upcoming Investor Conferences

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024.

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Edesa Biotech to Participate in Barclays Global Healthcare Conference

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management will participate in the Barclays 26th Annual Global Healthcare Conference, which is being held in Miami, Florida, from March 12-14, 2024. Attendees interested in meeting with Edesa can request meetings through conference organizers or by contacting the company at investors@edesabiotech.com.

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Edesa Biotech to Participate in Upcoming Dermatology Meetings

TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company plans to participate in the American Contact Dermatitis Society Annual Meeting on March 7, 2024 and the American Academy of Dermatology Annual Meeting from March 8-12, 2024 in San Diego, California. Attendees interested in meeting with Edesa can request meetings by contacting the company at investors@edesabiotech.com.

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2023 and provided an update on its business. During the first fiscal quarter, the company secured funding of up to C$23 million from the Canadian government toward the development of Edesa's ARDS (Acute Respiratory Distress Syndrome) drug candidate, EB05 (paridiprubart), a portion of which is conditionally repayable.

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

See News Rankings